Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:TBPH
- CUSIP: N/A
- Web: www.theravance.com
Capitalization:- Market Cap: $1.48892 billion
- Outstanding Shares: 53,829,000
Average Prices:- 50 Day Moving Avg: $34.24
- 200 Day Moving Avg: $35.37
- 52 Week Range: $23.15 - $43.44
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.27
- P/E Growth: -0.04
Sales & Book Value:- Annual Revenue: $31.36 million
- Price / Sales: 47.03
- Book Value: $4.48 per share
- Price / Book: 6.12
Profitability:- EBIDTA: ($211,250,000.00)
- Net Margins: -742.59%
- Return on Equity: -78.74%
- Return on Assets: -43.79%
Debt:- Debt-to-Equity Ratio: 0.93%
- Current Ratio: 6.74%
- Quick Ratio: 6.53%
Misc:- Average Volume: 276,850 shs.
- Beta: 2.24
- Short Ratio: 24.77
Frequently Asked Questions for Theravance Biopharma (NASDAQ:TBPH)
What is Theravance Biopharma's stock symbol?
Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."
How were Theravance Biopharma's earnings last quarter?
Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings results on Monday, August, 8th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $0.01. The company had revenue of $5.47 million for the quarter, compared to the consensus estimate of $6.19 million. Theravance Biopharma had a negative return on equity of 78.74% and a negative net margin of 742.59%. View Theravance Biopharma's Earnings History.
Where is Theravance Biopharma's stock going? Where will Theravance Biopharma's stock price be in 2017?
7 equities research analysts have issued 12-month price objectives for Theravance Biopharma's stock. Their predictions range from $24.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $42.57 in the next year. View Analyst Ratings for Theravance Biopharma.
What are analysts saying about Theravance Biopharma stock?
Here are some recent quotes from research analysts about Theravance Biopharma stock:
- 1. Needham & Company LLC analysts commented, "Theravance reported top-line results from Phase 2b trial of velusetrag in Gastroparesis. Statistically significant and dose-dependent improvements in gastric emptying were observed across all 3 doses tested. Symptomatic benefits, however, were only observed at lowest dose. Mgmt speculated that excessive gastric emptying into small intestine may have led to a separate set of symptoms negating any benefits. Explanation appears plausible, but we await details at future medical mtg. Regardless, efficacy in 5mg arm is sufficiently strong to justify Phase 3 development, considering both key pre-specified endpoints were met at 4wks (Gastroparesis Cardinal Symptom Index p=0.033 and Gastroparesis Rating Scale p=0.016), w/ all 10 subscales favoring drug over placebo. Effects were observed in both Diabetic and Idiopathic pts and persisted through 12wks. Mgmt plans to meet w/ FDA to discuss Phase 3 design." (8/2/2017)
- 2. According to Zacks Investment Research, "Theravance’s sole marketed product, Vibativ, continues to perform well, contributing meaningfully to the top line at the company. However, Vibativ witnessed a sequential decline due to seasonality and trends in surgical admissions. Nevertheless, the company’s efforts on the commercialization of Vibativ are encouraging. We are also positive on its efforts to expand the drug’s label, which if approved for additional indications, would be commercially significant. Further, its collaboration agreement with Mylan for revefenacin, a key late-stage pipeline candidate, is a big positive. Theravance’s progress with the rest of the pipeline is also impressive. Shares of the company have significantly outperformed the Medical-Drugs industry in 2016. Moreover, estimates have gone up ahead of the release of the company’s fourth-quarter 2016 results. However, Theravance’s heavy dependence on Vibativ for growth is concerning." (1/3/2017)
Who are some of Theravance Biopharma's key competitors?
Some companies that are related to Theravance Biopharma include Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Cambrex Corporation (CBM), Corcept Therapeutics Incorporated (CORT), Emergent Biosolutions (EBS), Pacira Pharmaceuticals (PCRX), Innoviva (INVA), Impax Laboratories (IPXL), AKCEA THERAPEUT (AKCA), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Lannett Co (LCI), Aceto Corporation (ACET), Aquinox Pharmaceuticals (AQXP) and Teligent (TLGT).
Who are Theravance Biopharma's key executives?
Theravance Biopharma's management team includes the folowing people:
- Rick E. Winningham, Chairman of the Board, Chief Executive Officer
- Renee D. Gala, Senior Vice President, Chief Financial Officer, Treasurer
- Bradford J. Shafer Esq. J.D., Executive Vice President, General Counsel, Secretary
- Brett K. Haumann M.D., Senior Vice President - Clinical Development and Chief Medical Officer
- Sharathchandra S. Hegde, Senior Vice President, Research
- Frank Pasqualone, Senior Vice President and Chief Commercial Operations Officer
- Kenneth R. Pitzer, Senior Vice President - Product Strategy and Commercial Planning
- Shehnaaz Suliman M.D., Senior Vice President - Corporate Development and Strategy
- Philip D. Worboys Ph.D., Senior Vice President, Translational Science
- William D. Young, Lead Independent Director
Who owns Theravance Biopharma stock?
Theravance Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Woodford Investment Management Ltd (20.06%), BlackRock Inc. (6.82%), Vanguard Group Inc. (5.99%), First Manhattan Co. (3.29%), State Street Corp (1.65%) and Northern Trust Corp (0.99%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Henrietta Fore, Plc Glaxosmithkline and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma.
Who sold Theravance Biopharma stock? Who is selling Theravance Biopharma stock?
Theravance Biopharma's stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Management Ltd., First Manhattan Co., Balyasny Asset Management LLC, Candriam Luxembourg S.C.A., Old West Investment Management LLC, Goldman Sachs Group Inc., Royce & Associates LP and California State Teachers Retirement System. Company insiders that have sold Theravance Biopharma stock in the last year include Bradford J Shafer and Brett K Haumann. View Insider Buying and Selling for Theravance Biopharma.
Who bought Theravance Biopharma stock? Who is buying Theravance Biopharma stock?
Theravance Biopharma's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Wells Fargo & Company MN, Alps Advisors Inc., State of Wisconsin Investment Board, Northern Trust Corp, TIAA CREF Investment Management LLC and Teachers Advisors LLC. Company insiders that have bought Theravance Biopharma stock in the last two years include Henrietta Fore, Plc Glaxosmithkline and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.
How do I buy Theravance Biopharma stock?
Shares of Theravance Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Theravance Biopharma's stock price today?
One share of Theravance Biopharma stock can currently be purchased for approximately $27.40.
MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Theravance Biopharma (NASDAQ:TBPH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 6 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.71) |
| Consensus Price Target: | $42.57 (55.37% upside) |
Analysts' Ratings History for Theravance Biopharma (NASDAQ:TBPH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/16/2017 | Evercore ISI | Initiated Coverage | Outperform -> Outperform | $45.00 | Medium |  |
| 8/16/2017 | Cantor Fitzgerald | Set Price Target | Buy | $55.00 | Low | |
| 8/2/2017 | Needham & Company LLC | Reiterated Rating | Buy | | High | |
| 5/10/2017 | Leerink Swann | Set Price Target | Buy | $47.00 | Low | |
| 3/22/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $42.00 | Medium | |
| 10/12/2016 | Robert W. Baird | Downgrade | Neutral -> Underperform | $19.00 -> $24.00 | N/A | |
| 9/19/2016 | Guggenheim | Reiterated Rating | Positive | $40.00 | N/A | |
| 8/3/2016 | Bank of America Corporation | Downgrade | Neutral -> Underperform | | N/A | |
(Data available from 8/19/2015 forward)
Earnings History for Theravance Biopharma (NASDAQ:TBPH)Earnings History by Quarter for Theravance Biopharma (NASDAQ TBPH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | 3/31/2017 | ($1.14) | ($1.27) | $5.07 million | $3.09 million | View | Listen | |
| 2/27/2017 | Q416 | ($1.05) | ($1.36) | $5.00 million | $5.69 million | View | Listen | |
| 8/8/2016 | Q216 | ($1.05) | ($1.06) | $6.19 million | $5.47 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.96) | ($1.10) | $18.69 million | $18.40 million | View | N/A | |
| 3/9/2016 | Q415 | ($1.62) | ($1.23) | ($280,000.00) million | $3.90 million | View | N/A | |
| 11/9/2015 | Q315 | ($1.44) | ($1.40) | $4.24 million | $10.70 million | View | N/A | |
| 8/10/2015 | Q215 | ($1.51) | ($1.42) | $4.25 million | $7.10 million | View | Listen | |
| 3/10/2015 | Q414 | ($1.70) | ($2.02) | $2.01 million | $1.30 million | View | N/A | |
| 11/6/2014 | Q3 14 | ($1.85) | ($1.72) | $1.08 million | $6.34 million | View | N/A | |
| 8/13/2014 | | ($0.56) | ($1.83) | $1.01 million | $2.97 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Theravance Biopharma (NASDAQ:TBPH)2017 EPS Consensus Estimate: ($4.68)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($1.04) | ($1.04) | ($1.04) |
| Q2 2017 | 1 | ($1.07) | ($1.07) | ($1.07) |
| Q3 2017 | 1 | ($1.26) | ($1.26) | ($1.26) |
| Q4 2017 | 1 | ($1.31) | ($1.31) | ($1.31) |
(Data provided by Zacks Investment Research)
Dividend History for Theravance Biopharma (NASDAQ:TBPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Theravance Biopharma (NASDAQ:TBPH)Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 82.77%
Insider Trades by Quarter for Theravance Biopharma (NASDAQ:TBPH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/11/2017 | Henrietta Fore | Director | Buy | 6,000 | $23.99 | $143,940.00 | |
| 8/11/2017 | Rick E Winningham | CEO | Buy | 10,000 | $24.50 | $245,000.00 | |
| 3/7/2017 | Brett K Haumann | SVP | Sell | 424 | $30.80 | $13,059.20 | |
| 3/6/2017 | Brett K Haumann | SVP | Sell | 13,576 | $31.52 | $427,915.52 | |
| 8/25/2016 | Brett K Haumann | SVP | Sell | 4,491 | $27.99 | $125,703.09 | |
| 8/22/2016 | Bradford J Shafer | EVP | Sell | 49,122 | $27.46 | $1,348,890.12 | |
| 8/19/2016 | Brett K Haumann | SVP | Sell | 9,509 | $27.97 | $265,966.73 | |
| 3/14/2016 | Plc Glaxosmithkline | Major Shareholder | Buy | 1,301,015 | $23,028,000.00 | $29,959,773,420,000.00 | |
| 10/7/2015 | Plc Glaxosmithkline | Major Shareholder | Buy | 44,574 | $607,544.00 | $27,080,666,256.00 | |
| 8/18/2015 | Burton G Malkiel | Director | Buy | 10,000 | $12.92 | $129,200.00 | |
| 8/18/2015 | Junning Lee | VP | Buy | 9,000 | $12.90 | $116,100.00 | |
| 8/17/2015 | Renee D Gala | CFO | Buy | 10,000 | $12.18 | $121,800.00 | |
| 8/17/2015 | Rick E Winningham | CEO | Buy | 80,000 | $11.86 | $948,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Theravance Biopharma (NASDAQ:TBPH)
Latest Headlines for Theravance Biopharma (NASDAQ:TBPH)
| Source: |
|
| Date | Headline |
|---|
 | Theravance Biopharma, Inc. (TBPH) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 18 at 4:42 AM |
| Cantor Fitzgerald Analysts Give Theravance Biopharma Inc (TBPH) a $55.00 Price Target
www.americanbankingnews.com - August 16 at 8:58 PM |
| Theravance Biopharma Inc (TBPH) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - August 16 at 5:40 PM |
| Zacks: Analysts Expect Theravance Biopharma, Inc. (NASDAQ:TBPH) Will Announce Quarterly Sales of $3.59 Million
www.americanbankingnews.com - August 12 at 1:34 PM |
 | See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
finance.yahoo.com - August 12 at 8:20 AM |
| Theravance Biopharma, Inc. (NASDAQ:TBPH) CEO Rick E. Winningham Purchases 10,000 Shares
www.americanbankingnews.com - August 11 at 8:16 PM |
| Theravance Biopharma, Inc. (NASDAQ:TBPH) Director Buys $143,940.00 in Stock
www.americanbankingnews.com - August 11 at 8:16 PM |
| Q3 2017 EPS Estimates for Theravance Biopharma, Inc. Decreased by Analyst (NASDAQ:TBPH)
www.americanbankingnews.com - August 11 at 8:12 AM |
| Theravance Biopharma, Inc. (TBPH) Expected to Post Earnings of -$1.14 Per Share
www.americanbankingnews.com - August 10 at 9:52 AM |
 | Theravance Biopharma (TBPH) Reports Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis
www.streetinsider.com - August 9 at 8:01 AM |
| Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis
finance.yahoo.com - August 9 at 8:01 AM |
| Theravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 9 at 8:01 AM |
| Edited Transcript of TBPH earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 8:01 AM |
 | Theravance Biopharma (TBPH) Updates On Results From Phase 2b Study Of Velusetrag - Slideshow
seekingalpha.com - August 5 at 7:36 AM |
| FY2020 EPS Estimates for Theravance Biopharma, Inc. Boosted by Leerink Swann (NASDAQ:TBPH)
www.americanbankingnews.com - August 4 at 7:58 PM |
| Corporate News Blog - Theravance Biopharma’s Velusetrag Successful in Mid-Stage Gastroparesis Study
finance.yahoo.com - August 4 at 8:54 AM |
| Theravance Biopharma, Inc. (TBPH) Downgraded by BidaskClub
www.americanbankingnews.com - August 2 at 7:36 PM |
| Theravance Biopharma's (NASDAQ:TBPH) "Buy" Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - August 2 at 4:38 PM |
| Theravance Biopharma to Report Second Quarter 2017 Financial Results and Business Update on August 8, 2017
finance.yahoo.com - August 2 at 7:39 AM |
| Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
finance.yahoo.com - August 2 at 7:39 AM |
| Theravance Biopharma, Inc. (NASDAQ:TBPH) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - August 1 at 11:04 PM |
| Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy
finance.yahoo.com - August 1 at 6:48 AM |
| Theravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : July 31, 2017
finance.yahoo.com - August 1 at 6:48 AM |
| Theravance Biopharma, Inc. (NASDAQ:TBPH) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:26 AM |
 | Oversold Conditions For Theravance Biopharma
www.nasdaq.com - July 29 at 7:45 AM |
| Notable Two Hundred Day Moving Average Cross - TBPH
www.nasdaq.com - July 28 at 8:33 AM |
| Theravance Biopharma, Inc. (TBPH) Cut to Sell at BidaskClub
www.americanbankingnews.com - July 27 at 8:30 PM |
| ETFs with exposure to Theravance Biopharma, Inc. : July 25, 2017
finance.yahoo.com - July 26 at 8:36 AM |
| Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 24 at 10:54 AM |
| Theravance Biopharma Inc (NASDAQ:TBPH) PT Set at $55.00 by Cantor Fitzgerald
www.americanbankingnews.com - July 23 at 4:20 PM |
| Brokerages Anticipate Theravance Biopharma, Inc. (TBPH) Will Announce Quarterly Sales of $4.06 Million
www.americanbankingnews.com - July 22 at 7:32 AM |
| Zacks: Analysts Anticipate Theravance Biopharma, Inc. (NASDAQ:TBPH) Will Post Earnings of -$1.13 Per Share
www.americanbankingnews.com - July 20 at 10:15 PM |
| Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : July 17, 2017
finance.yahoo.com - July 18 at 8:49 AM |
| ETFs with exposure to Theravance Biopharma, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 9:17 AM |
| Theravance Biopharma, Inc. to Post FY2017 Earnings of ($4.46) Per Share, Cantor Fitzgerald Forecasts (TBPH)
www.americanbankingnews.com - July 6 at 8:45 AM |
| Zacks: Analysts Anticipate Theravance Biopharma, Inc. (TBPH) Will Post Quarterly Sales of $4.06 Million
www.americanbankingnews.com - June 28 at 10:33 AM |
| Theravance Biopharma, Inc. (TBPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 27 at 9:26 AM |
| Zacks: Analysts Anticipate Theravance Biopharma, Inc. (TBPH) to Post -$1.13 EPS
www.americanbankingnews.com - June 26 at 8:40 PM |
| Theravance Biopharma, Inc. (TBPH) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - June 24 at 3:38 PM |
| Cantor Fitzgerald Initiates Coverage on Theravance Biopharma, Inc. (TBPH)
www.americanbankingnews.com - June 16 at 10:06 AM |
| Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : June 15, 2017
finance.yahoo.com - June 15 at 4:37 PM |
| Theravance (TBPH) Down 5.8% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 13 at 9:36 AM |
 | New Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin ...
www.prnewswire.com - June 7 at 10:00 AM |
| ETFs with exposure to Theravance Biopharma, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 6:42 PM |
| New Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin) Against Difficult-to-Treat MRSA and MSSA Pathogens Reported at ASM Microbe 2017
finance.yahoo.com - June 5 at 1:41 PM |
| Theravance Biopharma Inc (TBPH) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - June 3 at 12:57 AM |
| Theravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 3:17 PM |
| Theravance Biopharma Inc (TBPH) Expected to Post Quarterly Sales of $4.06 Million
www.americanbankingnews.com - June 2 at 1:12 PM |
| Zacks: Analysts Expect Theravance Biopharma Inc (TBPH) Will Post Earnings of -$1.16 Per Share
www.americanbankingnews.com - May 31 at 4:44 PM |
| Theravance Biopharma Inc (TBPH) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 31 at 10:02 AM |
Theravance Biopharma (TBPH) Chart for Saturday, August, 19, 2017
